LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Akciju saraksts・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Slēgts

3.59 -6.75

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.42

Max

3.79

Galvenie mērījumi
By Trading Economics
Ienākumi	-136K -35M
EPS	-0.503
Darbinieki	106
EBITDA	-619K -38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+88.17% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-11M 283M
Iepriekšējā atvēršanas cena	10.34
Iepriekšējā slēgšanas cena	3.59

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 4. jūn. 21:51 UTC

Galvenie tirgus virzītāji

Merlin Shares Rally After Defense Department's Design Review Wraps

2026. g. 4. jūn. 23:46 UTC

Tirgus saruna

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

2026. g. 4. jūn. 23:44 UTC

Tirgus saruna

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026. g. 4. jūn. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

2026. g. 4. jūn. 23:41 UTC

Iegādes, apvienošanās, pārņemšana

Energy Resources of Australia to Enter Trading Halt

2026. g. 4. jūn. 23:34 UTC

Tirgus saruna

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

2026. g. 4. jūn. 23:31 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 4. jūn. 23:08 UTC

Tirgus saruna

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

2026. g. 4. jūn. 22:41 UTC

Tirgus saruna

Australia Shares Set to Rise at the Open -- Market Talk

2026. g. 4. jūn. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 4. jūn. 20:44 UTC

Iegādes, apvienošanās, pārņemšana

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

2026. g. 4. jūn. 20:16 UTC

Tirgus saruna

Mexican Demand Indicators Show Signs of Life -- Market Talk

2026. g. 4. jūn. 20:15 UTC

Iegādes, apvienošanās, pārņemšana

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026. g. 4. jūn. 19:46 UTC

Tirgus saruna

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

2026. g. 4. jūn. 19:38 UTC

Tirgus saruna

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

2026. g. 4. jūn. 19:30 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

2026. g. 4. jūn. 18:47 UTC

Iegādes, apvienošanās, pārņemšana

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

2026. g. 4. jūn. 18:38 UTC

Peļņas

Money Quote: Tech Weakness in Context -- WSJ

2026. g. 4. jūn. 18:24 UTC

Peļņas

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 4. jūn. 17:09 UTC

Tirgus saruna

Retest of $55k Seen Possible for Bitcoin -- Market Talk

2026. g. 4. jūn. 16:58 UTC

Peļņas

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

2026. g. 4. jūn. 16:46 UTC

Tirgus saruna

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

2026. g. 4. jūn. 16:38 UTC

Peļņas

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

2026. g. 4. jūn. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 4. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 4. jūn. 16:13 UTC

Tirgus saruna

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

2026. g. 4. jūn. 16:11 UTC

Tirgus saruna

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

2026. g. 4. jūn. 15:56 UTC

Tirgus saruna

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

88.17% augšup

Prognoze 12 mēnešiem

Vidējais 7 USD 88.17%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

7 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 7 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.